Scarica l'app Stockscreener
0.6407
10.47%
0.0607
Dopo l'orario di chiusura:
.51
-0.1307
-20.40%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.58
Aprire:
$0.581
Volume 24 ore:
813.66K
Relative Volume:
0.37
Capitalizzazione di mercato:
$28.32M
Reddito:
-
Utile/perdita netta:
$-6.00M
Rapporto P/E:
-0.5126
EPS:
-1.25
Flusso di cassa netto:
$-31.01M
1 W Prestazione:
+15.28%
1M Prestazione:
-44.77%
6M Prestazione:
-35.93%
1 anno Prestazione:
-87.19%
Intervallo 1D:
$0.571
$0.65
Intervallo di 1 settimana:
$0.521
$0.65
Portata 52W:
$0.4641
$5.61
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Nome
Briacell Therapeutics Corp
Settore
Industria
Telefono
(604) 921-1810
Indirizzo
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Confronta BCTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
0.6407 | 28.32M | 0 | -6.00M | -31.01M | -1.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.11 | 104.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.15 | 78.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
621.29 | 37.15B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.28 | 30.22B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.79 | 27.76B | 3.30B | -501.07M | 1.03B | -2.1146 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-02-14 | Iniziato | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Borsa (BCTX) Ultime notizie
BriaCell Announces Proposed Effective Date of Share Consolidation - The Manila Times
BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025 - GlobeNewswire
BriaCell Announces Proposed Effective Date of Share Consolidation - GlobeNewswire Inc.
Bullish BriaCell Therapeutics Insider Buying Worth US$5.52m Yet To Pay Off - Simply Wall St
Insider Purchases Worth US$5.52m See Losses As BriaCell Therapeutics Market Value Drops To CA$40m - Yahoo Finance
BCTXBriacell Therapeutics Corp. Common Shares Latest Stock News & Market Updates - StockTitan
BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures - GlobeNewswire
BriaPro Therapeutics Corp. Announces Availability of Annual - GlobeNewswire
BriaPro Therapeutics Announces Digital Voting Process for 2025 Annual Meeting Amid Postal Strike - StockTitan
Vancouver biotech BriaCell to raise US$5.5 million in share offering - Business in Vancouver
BriaCell Therapeutics Corp. Reports Earnings Results for the First Quarter Ended October 31, 2024 - Marketscreener.com
BriaCell Therapeutics Corp. (BCTX) reports earnings - Quartz
BriaCell Therapeutics Reports Quarterly Financial Loss - TipRanks
BriaCell Therapeutics (OTCMKTS:BCTXF) and AbbVie (NYSE:ABBV) Head-To-Head Comparison - Defense World
BriaCell Therapeutics’ (BCTX) “Buy” Rating Reiterated at HC Wainwright - Defense World
BriaCell Therapeutics Announces Closing of $5.5 Million Public Offering - The Manila Times
BriaCell Therapeutics (CVE:BCT) Trading Down 3.8% – Here’s What Happened - Defense World
Briacell Therapeutics Corp (BCTX-Q) QuotePress Release - The Globe and Mail
BriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ - GlobeNewswire
BriaCell's Groundbreaking Cancer Treatment Shows Promise in Converting 'Cold' Tumors to 'Hot' in Clinical Trial - StockTitan
BriaCell Therapeutics Announces $5.5M Public Offering with 5-Year Warrants at $0.75 Per Share - StockTitan
BriaCell announces public offering of shares and warrants By Investing.com - Investing.com South Africa
BriaCell Therapeutics Announces Pricing of $5.5 Million Public Offering - The Manila Times
Certain Warrants of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 12-DEC-2024. - Marketscreener.com
BriaCell announces public offering of shares and warrants - Investing.com
BriaCell Therapeutics Announces Proposed Public Offering - GlobeNewswire
BriaCell Therapeutics Launches Public Offering of Shares and Warrants to Fund Growth Initiatives - StockTitan
BriaCell Presents Unprecedented Overall Survival Data in - GlobeNewswire
BriaCell's Cancer Immunotherapy Shows Breakthrough Results: Doubles Survival in Phase 2 Trial - StockTitan
HC Wainwright Analysts Lift Earnings Estimates for TSE:BCT - Defense World
HC Wainwright Reiterates Buy Rating for BriaCell Therapeutics (NASDAQ:BCTX) - Defense World
BriaCell Therapeutics (NASDAQ:BCTXW) Trading Up 12.2% – Here’s Why - Defense World
H.C. Wainwright reiterates Buy rating on Briacell Therapeutics stock - Investing.com
BriaCell Receives Green-Light from Data Safety Monitoring Board for Its Phase 3 Study in Metastatic Breast Cancer - Marketscreener.com
BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer - GlobeNewswire
BriaCell's Phase 3 Cancer Trial Clears Key Safety Review for Breast Cancer Treatment - StockTitan
BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive - GlobeNewswire
BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer - The Manila Times
BriaCell's Breast Cancer Therapy Shows 13.4-Month Survival Rate in Phase 2 Trial | BCTX Stock News - StockTitan
BriaCell announces board member resignation - Investing.com
BriaCell announces board member resignation By Investing.com - Investing.com UK
BriaCell Provides Update to its Board of Directors - The Manila Times
BriaCell Therapeutics Director Marc Lustig Steps Down from Board, Effective Immediately | BCTXW Stock News - StockTitan
BriaCell Therapeutics Corp. (BCT.TO) latest stock news and headlines - Yahoo Finance UK
U.S. Dollar/Rwanda Rwanda Francs (USDRWF) QuotePress Release - The Globe and Mail
BriaCell begins phase 1/2 trial of Bria-OTS™ for breast cancer | 2024-11-21 | Investing News - Stockhouse Publishing
BriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer Study - GlobeNewswire
BriaCell Launches Phase 1/2 Trial of Next-Gen Breast Cancer Immunotherapy | BCTX Stock News - StockTitan
Global X Equal Wght CDN Oil Gas Indx ETF (NRGY-T) QuotePress Release - The Globe and Mail
Global X Equal Weight Canadian Groceries & Stapl (MART-T) QuotePress Release - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp Down On Monday (BCT) - Barchart
Briacell Therapeutics Corp Azioni (BCTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.60%
2.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):